RESUMO
The human pathogen Clostridioides difficile colonises the gastrointestinal tract following antibiotic exposure, which causes perturbations in the beneficial microbiome. An unusual feature of C. difficile among the gut microbiota is its ability to produce high concentrations of the antimicrobial compound para-cresol, which selectively targets Gram-negative bacteria. Production of p-cresol occurs either by: (a) tyrosine fermentation via the intermediate para-hydroxyphenylacetate (p-HPA), or (b) direct turnover of exogenous p-HPA in the human gut. p-HPA is decarboxylated to produce p-cresol, by the action of HpdBCA decarboxylase encoded by the hpdBCA operon. HpdBCA decarboxylase production is induced at the transcriptional level by elevated p-HPA, which causes elevated p-cresol production, that significantly reduces microbiome diversity and richness. This deleterious effect of p-cresol on the beneficial gut microbiome is advantageous for C. difficile pathogenesis and infection relapse. Inhibiting this pathway would provide a highly specific therapeutic.
Assuntos
Carboxiliases , Clostridioides difficile , Infecções por Clostridium , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Carboxiliases/metabolismo , Carboxiliases/uso terapêutico , Clostridioides , Clostridioides difficile/genética , Infecções por Clostridium/microbiologia , Cresóis , Bactérias Gram-Negativas/metabolismo , HumanosRESUMO
BACKGROUND AND OBJECTIVES: To report final, 36-month safety and clinical outcomes from the PD-1101 trial of NBIb-1817 (VY-AADC01) in participants with moderately advanced Parkinson disease (PD) and motor fluctuations. METHODS: PD-1101 was a phase 1b, open-label, dose escalation trial of VY-AADC01, an experimental AAV2 gene therapy encoding the human aromatic l-amino acid decarboxylase (AADC) enzyme. VY-AADC01 was delivered via bilateral, intraoperative MRI-guided putaminal infusions to 3 cohorts (n = 5 participants per cohort): cohort 1, ≤7.5 × 1011 vector genomes (vg); cohort 2, ≤1.5 × 1012 vg; cohort 3, ≤4.7 × 1012 vg. RESULTS: No serious adverse events (SAEs) attributed to VY-AADC01 were reported. All 4 non-vector-related SAEs (atrial fibrillation and pulmonary embolism in 1 participant and 2 events of small bowel obstruction in another participant) resolved. Requirements for PD medications were reduced by 21%-30% in the 2 highest dose cohorts at 36 months. Standard measures of motor function (PD diary, Unified Parkinson's Disease Rating Scale III "off"-medication and "on"-medication scores), global impressions of improvement (Clinical Global Impression of Improvement, Patient Global Impression of Improvement), and quality of life (39-item Parkinson's Disease Questionnaire) were stable or improved compared with baseline at 12, 24, and 36 months following VY-AADC01 administration across cohorts. DISCUSSIONS: VY-AADC01 and the surgical administration procedure were well-tolerated and resulted in stable or improved motor function and quality of life across cohorts, as well as reduced PD medication requirements in cohorts 2 and 3 over 3 years. TRIAL REGISTRATION INFORMATION: NCT01973543. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that, in patients with moderately advanced PD and motor fluctuations, putaminal infusion of VY-AADC01 is well tolerated and may improve motor function.
Assuntos
Carboxiliases , Doença de Parkinson , Aminoácidos/genética , Aminoácidos/uso terapêutico , Antiparkinsonianos/efeitos adversos , Carboxiliases/uso terapêutico , Terapia Genética/métodos , Humanos , Doença de Parkinson/tratamento farmacológico , Qualidade de Vida , Resultado do TratamentoRESUMO
BACKGROUND: Antiglutamic acid decarboxylase (GAD)-associated neurologic disorders are rare, with varied presentations, including stiff-person syndrome (SPS) and cerebellar ataxia (CA). Vestibular and ocular motor (VOM) dysfunction can be the main presentation in a subset of patients. METHODS: Retrospective review of the Johns Hopkins Hospital medical records from 1997 to 2018 identified a total of 22 patients with a diagnosis of anti-GAD-associated SPS or CA who had detailed VOM assessments. Eight had prominent VOM dysfunction at the initial symptom onset and were referred to neurology from ophthalmology or otolaryngology ("early dominant"). Fourteen patients had VOM dysfunction that was not their dominant presentation and were referred later in their disease course from neurology to neuro-ophthalmology ("nondominant"). We reviewed clinical history, immunological profiles, and VOM findings, including available video-oculography. RESULTS: In the 8 patients with early dominant VOM dysfunction, the average age of symptom onset was 53 years, and 5 were men. The most common symptom was dizziness, followed by diplopia. Seven had features of CA, and 4 had additional features of SPS. None had a structural lesion on brain MRI accounting for their symptoms. The most common VOM abnormalities were downbeating and gaze-evoked nystagmus and saccadic pursuit. All received immune therapy and most received symptomatic therapy. Most experienced improvement in clinical outcome measures (modified Rankin scale and/or timed 25-foot walk test) or VOM function. By contrast, in the 14 patients in whom VOM dysfunction was nondominant, most had an SPS phenotype and were women. VOM abnormalities, when present, were more subtle, although mostly still consistent with cerebellar and/or brainstem dysfunction. CONCLUSIONS: Individuals with anti-GAD-associated neurologic disorders may present with prominent VOM abnormalities at the initial symptom onset that localize to the cerebellum and/or brainstem. In our cohort, immune and symptomatic therapies improved clinical outcomes and symptomatology.
Assuntos
Carboxiliases , Ataxia Cerebelar , Doenças do Sistema Nervoso , Rigidez Muscular Espasmódica , Carboxiliases/uso terapêutico , Ataxia Cerebelar/complicações , Movimentos Oculares , Feminino , Glutamato Descarboxilase , Humanos , Rigidez Muscular Espasmódica/complicações , Rigidez Muscular Espasmódica/diagnóstico , Rigidez Muscular Espasmódica/terapiaRESUMO
PURPOSE: To evaluate the potential of ALLN-177, an orally administered, oxalate-specific enzyme therapy to reduce urine oxalate (UOx) excretion in patients with secondary hyperoxaluria. METHODS: Sixteen male and female subjects with both hyperoxaluria and a kidney stone history were enrolled in an open-label study. Subjects continued their usual diets and therapies. During a 3-day baseline period, two 24-h (24-h) urines were collected, followed by a 4-day treatment period with ALLN-177 (7,500 units/meal, 3 × day) when three 24-h urines were collected. The primary endpoint was the change in mean 24-h UOx from baseline. Safety assessments and 24-h dietary recalls were performed throughout. RESULTS: The study enrolled 5 subjects with enteric hyperoxaluria and 11 with idiopathic hyperoxaluria. ALLN-177 was well tolerated. Overall mean (SD) UOx decreased from 77.7 (55.9) at baseline to 63.7 (40.1) mg/24 h while on ALLN-177 therapy, with the mean reduction of 14 mg/24 h, (95% CI - 23.71, - 4.13). The calcium oxalate-relative urinary supersaturation ratio in the overall population decreased from a mean of 11.3 (5.7) to 8.8 (3.8) (- 2.8; 95% CI - 4.9, - 0.79). This difference was driven by oxalate reduction alone, but not any other urinary parameters. Mean daily dietary oxalate, calcium, and fluid intake recorded by frequent diet recall did not differ by study periods. CONCLUSION: ALLN-177 reduced 24-h UOx excretion, and was well tolerated. The results of this pilot study provided justification for further investigation of ALLN-177 in patients with secondary hyperoxaluria. TRIAL REGISTRATION: Clinicaltrials.gov NCT02289755.
Assuntos
Carboxiliases/uso terapêutico , Hiperoxalúria/tratamento farmacológico , Hiperoxalúria/urina , Oxalatos/urina , Administração Oral , Adulto , Idoso , Carboxiliases/administração & dosagem , Dieta , Terapia Enzimática , Feminino , Humanos , Hiperoxalúria/complicações , Cálculos Renais/complicações , Masculino , Pessoa de Meia-IdadeRESUMO
Introduction: Currently, three types of primary hyperoxaluria (PH I-III) are known, all based on different gene-mutations affecting the glyoxylate metabolism in the liver. Disease hallmark is an increased endogenous oxalate production and thus massively elevated urinary excretion of oxalate and other type-specific metabolites. Hyperoxaluria induces the formation of calcium-oxalate kidney stones and/or nephrocalcinosis. In addition to that, a chronic inflammasome activation by hyperoxaluria per se, often leads to an early deterioration of kidney function, regularly resulting in end-stage renal disease (ESRD) at least in patients with type I PH. Except for vitamin B6 treatment in PH I, therapeutic regimen nowadays consists only of supportive measures, like significantly increased fluid intake and medication increasing the urinary solubility like alkaline citrate. Areas covered: Disease burden can be severe, and both clinicians and scientist are eager in finding new therapeutic approaches. The currently ongoing clinical studies and promising research in this field are reported in this paper. To present a complete overview, we searched electronic databases, like Clinical trial gov, National Center for Biotechnology Information PubMed, congress reports, press releases and personal information acquired at congresses and conventions. Searches were conducted using the following medical headings: (primary) hyperoxaluria, PH, therapy, treatment and research. Expert opinion: There is light on the horizon that new treatment options will be available in due time, as there are several promising therapeutic agents currently under investigation, some being at the first levels of drug development, but some already in ongoing clinical trials (phase I-III).
Assuntos
Hiperoxalúria Primária/terapia , Animais , Carboxiliases/uso terapêutico , Humanos , Oxalobacter formigenes , Interferência de RNARESUMO
BACKGROUND: Wound healing is a dynamic process that normally follows a predictable cascade of events. A common cause of delayed wound healing or wound dehiscence is increased colonization with microbes, often leading to infection. Infection may impede the healing process by inducing an undesirable inflammatory response. Systemic antibiotics and topical antiseptics are mainstays of treatment, but their adverse side effects and the potential for emergence of resistant microbial strains have led to a search for alternative approaches for control of bioburden. CASES: We describe two neonates and one 10-year-old girl who experienced delayed wound healing treated with a nonmedicated dressing that exploits bacterial cell-surface hydrophobic interactions via a dressing with a fatty acid (dialkylcarbamoylchloride [DACC]) coating. This dressing was used in a colonized, unstageable occipital pressure injuries, an infected stage 4 pressure injury over a vertebra, and a dehisced surgical sternal wound. Complete closure was achieved in all wounds within 2 to 4 weeks. CONCLUSION: We employed a DACC-coated dressing that provides bacteriostatic activity without creating cytotoxicity or an inflammatory response.
Assuntos
Bandagens/normas , Carboxiliases/uso terapêutico , Cicatrização/efeitos dos fármacos , Antibacterianos/uso terapêutico , Bandagens/microbiologia , Carboxiliases/farmacologia , Criança , Humanos , Interações Hidrofóbicas e Hidrofílicas/efeitos dos fármacos , Lactente , Deiscência da Ferida Operatória/tratamento farmacológico , Infecção da Ferida Cirúrgica/tratamento farmacológico , Cicatrização/fisiologiaRESUMO
BACKGROUND: Hyperoxaluria may result from increased endogenous production or overabsorption of dietary oxalate in the gastrointestinal tract leading to nephrolithiasis and, in some, to oxalate nephropathy and chronic kidney disease. ALLN-177 is an oral formulation of a recombinant, oxalate specific, microbial enzyme oxalate decarboxylase intended to treat secondary hyperoxaluria by degrading dietary oxalate in the gastrointestinal tract, thereby reducing its absorption and subsequent excretion in the urine. METHODS: This double-blind, placebo controlled, randomized, cross-over, phase 1 study of ALLN-177 evaluated the tolerability of ALLN-177 and its effect on urinary oxalate excretion in 30 healthy volunteers with hyperoxaluria induced by ingestion of a high oxalate, low calcium (HOLC) diet. The primary end point was the difference in the mean 24-hour urinary oxalate excretion during the ALLN-177 treatment period compared with the placebo treatment period. RESULTS: The daily urinary oxalate excretion increased in the study population from 27.2 ± 9.5 mg/day during screening to 80.8 ± 24.1 mg/day (mean ± SD) on the HOLC diet before introducing ALLN-177 or placebo therapy for 7 days. Compared to placebo, ALLN-177 treatment reduced urinary oxalate by 11.6 ± 2.7 mg/day, p = 0.0002 (least squares mean ± SD). CONCLUSIONS: In healthy volunteers, with diet-induced hyperoxaluria treatment with ALLN-177, when compared to placebo, significantly reduced urinary oxalate excretion by degrading dietary oxalate in the gastrointestinal tract and thereby reducing its absorption. ALLN-177 may represent a new approach for managing secondary hyperoxaluria and its complications.
Assuntos
Bacillus subtilis/enzimologia , Proteínas de Bactérias/uso terapêutico , Carboxiliases/uso terapêutico , Hiperoxalúria/tratamento farmacológico , Cálculos Renais/prevenção & controle , Oxalatos/metabolismo , Administração Oral , Adulto , Proteínas de Bactérias/administração & dosagem , Proteínas de Bactérias/efeitos adversos , Carboxiliases/administração & dosagem , Carboxiliases/efeitos adversos , Estudos Cross-Over , Dieta/efeitos adversos , Método Duplo-Cego , Feminino , Absorção Gastrointestinal/efeitos dos fármacos , Voluntários Saudáveis , Humanos , Hiperoxalúria/induzido quimicamente , Hiperoxalúria/urina , Masculino , Pessoa de Meia-Idade , Oxalatos/farmacologia , Oxalatos/urina , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Eliminação RenalRESUMO
Renal urolithiasis is a pathological condition common to a multitude of genetic, physiological and nutritional disorders, ranging from general hyperoxaluria to obesity. The concept of quickly dissolving renal uroliths via chemolysis, especially calcium-oxalate kidney stones, has long been a clinical goal, but yet to be achieved. Over the past 25 years, there has been a serious effort to examine the prospects of using plant and microbial oxalate-degrading enzymes known to catabolize oxalic acid and oxalate salts. While evidence is emerging that bacterial probiotics can reduce recurrent calcium-oxalate kidney stone disease by lowering systemic hyperoxaluria, the possible use of free oxalate-degrading enzyme therapy remains a challenge with several hurdles to overcome before reaching clinical practice.
Assuntos
Oxalato de Cálcio/metabolismo , Carboxiliases/uso terapêutico , Cálculos Renais/terapia , Oxalatos/metabolismo , Microbioma Gastrointestinal , Humanos , Oxalobacter formigenes/metabolismo , Probióticos/uso terapêutico , RecidivaRESUMO
Periodontal disease, gingival inflammation (gingivitis) and periodontal attachment loss (periodontitis), causes tooth loss and susceptibility to chronic inflammation. Professionally scaling and cleaning the teeth regularly controls the disease, but is expensive in companion animals. Eikenella corrodens is common in canine oral cavities where it is a source of lysine decarboxylase (LDC). In human dental biofilms (plaques), LDC converts lysine to cadaverine and impairs the gingival epithelial barrier to bacteria. LDC vaccination may therefore retard gingivitis development. Year-old beagle dogs provided blood samples, and had weight and clinical measurements (biofilm and gingivitis) recorded. After scaling and cleaning, two dogs were immunized subcutaneously with 0.2mg native LDC from E. corrodens and 2 sets of four dogs with 0.2mg recombinant LDC purified from Escherichia coli. A third set of 4 dogs was immunized intranasally. Rehydragel(®), Emulsigen(®), Polygen™ or Carbigen™ were used as adjuvant. Four additional pairs of dogs were sham-immunized with each adjuvant alone (controls). Immunizations were repeated twice, 3 weeks apart, and clinical measurements were obtained after another 2 weeks, when the teeth were scaled and cleaned again. Tooth brushing was then stopped and the diet was changed from hard to soft chow. Clinical measurements were repeated after 1, 2, 3, 4, 6 and 8 weeks. Compared with sham-immunized dogs, gingivitis was reduced over all 8 weeks of soft diet after subcutaneous immunization with native LDC, or after intranasal immunization with recombinant LDC in Carbigen™, but for only 6 of the 8 weeks after subcutaneous immunization with recombinant LDC in Emulsigen(®) (repeated measures ANOVA). Subcutaneous vaccination induced a strong serum IgG antibody response that decreased during the soft diet period, whereas intranasal immunization induced a weak serum IgA antibody response that did not decrease. Immunization with recombinant LDC may provide protection from gingivitis if procedures are optimized.
Assuntos
Carboxiliases/uso terapêutico , Gengivite/veterinária , Imunização/veterinária , Periodontite/veterinária , Sequência de Aminoácidos , Animais , Formação de Anticorpos , Sequência de Bases , Biofilmes , Cadaverina/biossíntese , Carboxiliases/imunologia , Cães , Eikenella corrodens/enzimologia , Gengivite/prevenção & controle , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Dados de Sequência Molecular , Índice Periodontal , Periodontite/prevenção & controle , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/uso terapêutico , Escovação DentáriaRESUMO
Interest has recently been revived in enzymes that degrade essential amino acids. Arginine-catabolizing enzymes now predominate and are discussed in this review. Apart from reducing tumor load through cell death occurring as a result of deprivation alone, these catabolic enzymes conveniently leave the remaining malignant cells vulnerable to other therapeutic modalities through combinatorial treatments with cycle-dependent drugs, the timing of additional treatment after deprivation being crucial.
Assuntos
Antineoplásicos/metabolismo , Antineoplásicos/uso terapêutico , Arginase/metabolismo , Arginase/uso terapêutico , Arginina/metabolismo , Neoplasias/tratamento farmacológico , Neoplasias/enzimologia , Animais , Arginase/farmacologia , Arginina/antagonistas & inibidores , Arginina/deficiência , Carboxiliases/metabolismo , Carboxiliases/uso terapêutico , Humanos , Neoplasias/metabolismoRESUMO
Antecedentes: La cocarboxilasa no degradable (CND), es una coenzima importante para la síntesis de la deshidrogenasa pirúvica, enzima que regula el catabolismo del piruvato y posiblemente la clave para la recuperación de la acidosis metabólica. Objetivo: Evaluar la eficacia de la cocarboxilasa no degradable para manejar la acidosis metabólica del recién nacido. Material y métodos: Se realizó un estudio doble ciego controlado, seleccionado aleatoriamente 30 neonatos durante un año, con diagnóstico gasométrico de acidosis metabólica (pH de 7.30 o menos, bicarbonato de 18 o menos, y exceso de base de -9 o mayor). Se administró solución isotónica de cloruro de sodio (grupo I) 1ml/kg, bicarbonato de sodio (grupo II) 2mEq/kg y CND (grupo III) a razón de 40 mg/kg. El volumen en todos los casos fue de 1 mL/kg. La primera dosis se administró en cuanto se realizó el diagnóstico y las dos siguientes con espacio de 8 horas. Se determinó el efecto de las sustancias en el pH y la corrección de la acidosis metabólica. Resultados: Los resultados mostraron un discreto aumento del pH con la CND sin diferencias para ninguna de las sustancias sobre la acidosis metabólica
Assuntos
Recém-Nascido , Humanos , Acidose/enzimologia , Carboxiliases/farmacocinética , Carboxiliases/uso terapêutico , Bicarbonato de Sódio/uso terapêutico , Cloreto de Sódio/uso terapêuticoRESUMO
The effect of levodopa (L-dopa), alone or in combination with a peripheral decarboxylase inhibitor (PDI), on plasma levels of aromatic-L-amino acid decarboxylase (ALAAD, = dopa decarboxylase), L-dopa, 3-O-methyl-dopa (3-OMD), dopamine (DA), noradrenaline, adrenaline and dopamine beta-hydroxylase has been studied. In healthy subjects and in patients with parkinsonism plasma ALAAD level fell after administration of L-dopa + benserazide, but returned to previous levels within 90 min. In a cross-sectional study blood was obtained, 2 h after dosing, from 104 patients with idiopathic parkinsonism, divided into four groups: no L-dopa treatment (group 1), L-dopa alone (group 2), L-dopa + benserazide (Madopar) (group 3) and L-dopa + carbidopa (Sinemet) (group 4). Plasma ALAAD, which was normal in groups 1 and 2, was increased 3-fold in groups 3 and 4, indicating that there was induction of ALAAD by the co-administration of PDI. Despite this induction of ALAAD, in groups 3 and 4, with half the daily L-dopa dose compared with group 2, plasma L-dopa and 3-OMD levels were 5 times higher, while plasma DA levels were not different. The DA/L-dopa ratio was decreased 5-fold in group 2 and 16-fold in groups 3 and 4 as compared with group 1. Neither 3-OMD levels nor 3-OMD/L-dopa ratios correlated with the occurrence of on-off fluctuations. In a longitudinal study of three patients started on Madopar treatment the induction of plasma ALAAD was found to occur gradually over 3-4 weeks. Further detailed pharmacokinetic studies in plasma and cerebrospinal fluid are required in order to elucidate whether the ALAAD induction by PDI may be related to the loss of clinical efficacy of combination therapy in some patients and how it is related to end-of-dose deterioration and on-off phenomena.
Assuntos
Carboxiliases/antagonistas & inibidores , Levodopa/uso terapêutico , Doença de Parkinson/tratamento farmacológico , Administração Oral , Idoso , Benserazida/sangue , Benserazida/farmacocinética , Benserazida/uso terapêutico , Carboxiliases/administração & dosagem , Carboxiliases/sangue , Carboxiliases/uso terapêutico , Catecolaminas/sangue , Dopa Descarboxilase/sangue , Combinação de Medicamentos/sangue , Combinação de Medicamentos/farmacocinética , Combinação de Medicamentos/uso terapêutico , Quimioterapia Combinada , Feminino , Humanos , Levodopa/sangue , Levodopa/farmacocinética , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Fenitoína/farmacocinética , Fenitoína/uso terapêutico , Fatores de Tempo , Tirosina/análogos & derivados , Tirosina/sangueRESUMO
The supine and erect arterial blood pressure and pulse rate were measured in 13 patients with Parkinson's disease, chronically treated with levodopa and peripheral decarboxilase inhibitors presenting with or without On-Off phenomenon (end-of-dose akinesia). In the patients with dose-related response fluctuations the mean systo-diastolic blood pressure, both supine and erect, was found significantly higher during the Off phase as compared to the On phase and to that of the control group (patients with stable clinical response). The mean diurnal "excursion" of systo-diastolic supine and erect blood pressure in patients with On-Off phenomenon was significantly larger than in the control group. Although the clinical implications of such findings remain to be established, the results of this study indicate that arterial blood pressure fluctuations are a definite autonomic component of end-of-dose akinesia.
Assuntos
Pressão Sanguínea , Doença de Parkinson/fisiopatologia , Sistema Nervoso Autônomo/fisiopatologia , Carboxiliases/uso terapêutico , Feminino , Humanos , Técnicas In Vitro , Levodopa/uso terapêutico , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/tratamento farmacológico , PosturaRESUMO
The effect of decarboxylase (DC)-blocked L-dopa (proportion of 4: 1) on respiratory function was tested by spirometry in 30 patients with Parkinson's disease. It was possible to improve restrictive ventilatory abnormalities of extra-pulmonary origin (weakness of respiratory musculature). Vital capacity (VC) increased by 0.21 litre. Thisincrease was due to a raised inspiratory capacity and thus an increase in the active part of ventilation. Forced expiration volume (FEV1) was improved by 0.32 litre, FEV1/VC remaining unchanged, which demonstrates that the restrictive ventilatory abnormality was affected. Inspiratory volume (VT) and minute volume at constant respiratory rate increased by 0.07 and 1.171, respectively. These results must be interpreted with caution, but they suggest a raised metabolic level with regained mobility during treatment. All quoted results, except those of respiratory rate and minute volume, were statistically significant (2 mu equals 0.01).
Assuntos
Carboxiliases/uso terapêutico , Levodopa/uso terapêutico , Doença de Parkinson/fisiopatologia , Respiração , Sistema Respiratório/fisiopatologia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/tratamento farmacológico , Espirometria , Capacidade VitalRESUMO
Twelve parkinsonian patients with an unsatisfactory therapeutic result on L-Dopa alone due to nausea, vomiting and involuntary movements were treated WITH L-Dopa and decarboxylase inhibitor. The daily dose reached 800mg L-Dopa and 200 mg decarboxylase inhibitor. Single doses of each of the components were also given. Electrophysiological examination of hypokinesia, tremor and rigidity, and clinical observation revealed clear evidence of rapid improvement on small doses of L-Dopa combined with decarboxylase inhibitor. Most of the improvement occurred during the 1st week before the maximal dose was reached. A single oral dose of decarboxylase inhibitor resulted in an improvement, suggesting the presence in the organism of a small AMOUNT OF L-Dopa. This work also shows the absence of liver toxicity of the drug used. Elimination of the extracerebral side effects nausea and vomiting in our opinion is a principle advantage of the compound compared to L-Dopa alone, wheras abnormal involuntary movements, which were found in all patients, remain the limiting adverse side effect.